TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration-Time Curve (AUC) From Time 0 to 168 Hours Postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of Fall
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain Interference and Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with positive findings in skin tests, allergen-specific IgE or drug provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Xerosis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pruritus evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Test of Pre-morbid Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in NAB Attention Module
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of participants reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants reporting systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants reporting serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants receiving latozinemab
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of treatment with latozinemab
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tendon Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence and severity of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Screening-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in negative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spinal Cord Cross-Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal Cord Corticospinal Tract (CST) Fractional Anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Divarasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Hour 0 to the last measurable concentration (AUC0-t) of Divarasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar quality (POSAS v2.0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biopsy-proven histologic resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Reversal Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entrance to bladder time (ETBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of TRAIPTA procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with complete response to Tarlatamab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with partial response to Tarlatamab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ability of critical thinking and clinical reasoning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: velocity displacement of CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of dose interruption or discontinuation of study treatment due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: MTD or the recommended phase two dose (RP2D) of BNT317
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in number of migraine days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Adherence to Exercise Coaching Sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-Earthquake Trauma Symptoms Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trait Hope Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Teoxane Infraorbital Hollows Scale (TIOHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Single Leg Squat Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single Leg Landing Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Drop Jump Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety climate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pulsatility index of umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resistive index of umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulsatility index of fetal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resistive index of fetal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of pixantrone as bridging therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclinometer measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical-laboratory presentation of pediatric acute hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Menstrual Symptoms Questionnaire (MSQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Liver stiffness measurements (LSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of accurate airway verifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pathological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of SCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life measured with EORTC QLQ C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured with EORTC QLQ-BR42
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured with BREAST-Q
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adoption (uptake)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to last time of measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-∞ )
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: factor level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safe apnoea time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants Who Scored Above the Midpoint on the Client Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postoperative analgesic doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of VOC biomarkers for gastrointestinal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Device-or procedure-related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure- and device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Refractoriness to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls Risk Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT/McGill Body Image Concern Scale - Head and Neck Cancer Version (FACT-MBIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prostate size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Vital Sign Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Range of Motion Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand grip strength measurement with Jamar Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life by International Incontinence Counseling Questionnaire - Short Form (ICIQ - SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pelvic floor muscle strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting vaginal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performances assessed using N-back tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performances assessed using Psychomotor Vigilance task (PVT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performances assessed using Paced Visual Serial Addition Task (PVSAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insulinotropic effect (C-peptide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CTX (bone resorption marker)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Medical Research Council Dyspnea scale (mMRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: COPD assessment Test (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Grade 2-5 Dyspnea
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to provide oxygenation during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to provide ventilation during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Laryngopharyngeal Measure of Perceived Sensation (LUMP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eating Assessment Tool-10 (EAT-10)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numeric Rating Scale for throat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesic use
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of complete occlusion of the aneurysm with Contour at one (1) year after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of serum albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Physician assessment of catheter navigation and visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician assessment of ICE markers and geometry usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SF-36 Physical Function Component Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of oral raw apple syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in urges to use CSAM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of genes causing COEH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stress/mental Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sleep Quantity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in adolescents' coping skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in adolescents' emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in adolescents' general anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended Dose (RDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, severity, and relationship of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, severity, and relationship of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with changes from baseline in ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with changes in clinical laboratory values over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of oral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of 225Ac-MTI-201
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Serious or Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Terminal half life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of adverse maternal and birth outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calcium score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coro-scanner plaque size variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coro-scanner plaque density variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caregiver Burden at End of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Patient Distress at End of Treatment (CESD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amplitude of neurophysiological response to cannabis cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total morphine requirement in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With CDAI Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma doxycycline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ejaculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of HSIL recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion of scheduled eVisits
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Emergency Department (ED) utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Hamilton Depression Rating Scale (HDRS)-21 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proximal Cuff Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plantar Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar Force Impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Socket Comfort Score (Comfort)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse Event of Myelosuppression
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event of Hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event of Posterior Reversible Encephalopathy Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event of Interstitial Lung Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event of Secondary Malignant Tumors
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event of Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Significance of TRPC6 coding sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in trabecular microarchitecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMRI data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PET-FDG regional standardized data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PET-FDG global data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG connectivity data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG Frequency band data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute change in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics/pharmacodynamics endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With one or More Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Clinical Global Impression Improvement Scale (CGI-I) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in LDL-C, HDL-C, Total cholesterol, and Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myopathy complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Relative concentrations of key metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immediate success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Dyspareunia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Non-cyclical pelvic pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Endometriosis foci regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Casual Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Engagement in Treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Antibiotic resistance profile of S. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing